Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: Implication for a new therapeutic approach

Pathology International

Volumn 55, Issue 12, 2005, Pages 757-765

  Murakawa, Tetsuya ^a   Tsuda, Hitoshi ^a   Tanimoto, Takao ^a   Tanabe, Tetsuya ^a   Kitahara, Satoshi ^a   Matsubara, Osamu ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

EGFR (c erbB 1, HER 1); HER 2 (c erbB 2); Immunohistochemistry; KIT; Real time PCR; Tyrosine phosphorylation; Undifferentiated thyroid carcinoma; Western blot analysis

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CANCER THERAPY; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; THYROID CARCINOMA; UNDIFFERENTIATED CARCINOMA; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, MESSENGER; THYROID NEOPLASMS; TYROSINE;

EID: 30944466245     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01902.x     Document Type: Article

References (41)

1. Stanley RB. Malignant neoplasms of the oral cavity. In: Charles WC, John MF, Lee AH, Charles JK, David ES, eds. Otolaryngology-Head and Neck Surgery. St Louis: Mosby, 1986; 1281-343.
2. John MF, Rockne LB. Neoplasms of the thyroid. In: Charles WC, John MF, Lee AH, Charles JK, David ES, eds. Otolaryngology-Head and Neck Surgery. St Louis: Mosby, 1986; 2511-24.
3. Yarden Y, Kuang WJ, Yang-Feng T et al. Human protooncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341-51.
4. Qiu FH, Ray P, Brown K et al. Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family-oncogene activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988; 7: 1003-11.
5. Furitsu T, Tsujimura T, Tono T et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-44.
6. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature (Lond) 1995; 373: 347-9.
7. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (Washington DC) 1995; 279: 577-80.
8. Costa MJ, Walls J. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases. Cancer 1996; 77: 533-42.
9. Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-90.
10. Yonemura Y, Ninomiya I, Ohoyama S et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991; 67: 2914-18.
11. Marti U, Ruchti C, Kampf J et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 2001; 11: 137-45.
12. Fluge O, Akslen LA, Haugen DR, Varhaug JE, Lillehaug JR. Expression of heregulins and associations with the ErbB family of tyrosine kinase receptors in papillary thyroid carcinomas. Int J Cancer 2000; 87: 763-70.
13. Westermark K, Lundqvist M, Wallin G et al. EGF-receptors in human normal and pathological thyroid tissue. Histopathology 1996; 28: 221-7.
14. Chen BK, Ohtsuki Y, Furihata M et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999; 15: 893-8.
15. Ensinger C, Spizzo G, Moser P et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann NY Acad Sci 2004; 1030: 69-77.
16. Mondi MM, Rich R, Ituarte P et al. HER2 expression in thyroid tumors. Am Surg 2003; 69: 1100-3.
17. Kato S, Kobayashi T, Yamada K et al. Expression of erbB receptors mRNA in thyroid tissues. Biochim Biophys Acta 2004; 1673: 194-200.
18. Gumurdulu D, Uguz A, Erdogan S, Tuncer I, Demircan O. Expression of c-erbB-2 oncoprotein in different types of thyroid tumors: An immunohistochemical study. Endocr Res 2003; 29: 465-72.
19. Ensinger C, Prommegger R, Kendler D et al. Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. Anticancer Res 2003; 23: 2349-53.
20. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: Value in the diagnosis of mast cell disorders. Hum Pathol 1998; 29: 498-504.
21. Fernebro E, Bendahl PO, Dictor M, Persson A, Ferno M, Nilbert M. Immunohistochemical patterns in rectal cancer: Application of tissue microarray with prognostic correlations. Int J Cancer 2004; 111: 921-8.
22. Tsuura Y, Hiraki H, Watanabe K et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: Immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994; 424: 135-41.
23. Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: Implications for a new therapeutic approach. Mod Pathol 2003; 16: 1035-40.
24. Hornick JL, Fletcher CD. Validating immunohistochemical staining for KIT (CD117). Am J Clin Pathol 2003; 119: 325-27.
25. Chan JL, Lai M, Wang LH. Effect of dimerization on signal transduction and biological function of oncogenic Ros, insulin, and insulin-like growth factor I receptors. J Biol Chem 1997; 272: 146-53.
26. Baudhuin LM, Jiang Y, Zaslavsky A, Ishii I, Chun J, Xu Y. S1P3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB J 2004; 18: 341-43.
27. Kaabeche K, Lemonnier J, Le Mee S, Caverzasio J, Marie PJ. Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation. J Biol Chem 2004; 279: 36259-67.
28. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
29. Cardoso F, Durbecq V, Larsimont D et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24: 201-9.
30. Pushkarev VM, Starenki DV, Saenko VA et al. Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology 2004; 145: 3143-52.
31. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
32. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002; 20: 2240-50.
33. Baselga J. The EGFR as a target for anticancer therapy: Focus on cetuximab. Eur J Cancer 2001; 37: S16-S22.
34. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
35. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
36. Chen B, van den Brekel MW, Buschers W, Balm AJ, van Velthuysen ML. Validation of tissue array technology in head and neck squamous cell carcinoma. Head Neck 2003; 25: 922-30.
37. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003; 25: 67-73.
38. Rikimaru K, Tadokoro K, Yamamoto T, Enomoto S, Tsuchida N. Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 1992; 14: 8-13.
39. Caponigro F, Ionna F, Comella G. New cytotoxic and molecular-targeted therapies of head and neck tumors. Curr Opin Oncol 2004; 16: 225-30.
40. Caponigro F. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer. Anticancer Drugs 2004; 15: 311-20.
41. Cohen EE, Rosen F, Stadler WM et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-87.